China NMPA Product Recall - Triiodothyronine amino acid assay kit (direct chemiluminescence method)

The National Medical Products Administration (NMPA) issued a public notice on October 11, 2017, detailing a voluntary Class III recall initiated by Siemens Medical Diagnostics Products (Shanghai) Co., Ltd. The recall pertains to their Triiodothyronine Assay Kit (Direct Chemiluminescence Method), specifically identified by Registration No. 20162404411. While the specific underlying violation or technical issue necessitating the recall is not explicitly detailed within this summary document, the company proactively undertook this measure to address an identified concern with the medical device. A Class III recall, as designated by regulatory bodies, signifies that the use of or exposure to a violative product is not likely to cause adverse health consequences, but the product still deviates from regulatory standards or specifications. The regulatory oversight for this recall falls under the purview of the NMPA, which functions as China's primary authority for regulating medical products, ensuring their safety, quality, and efficacy within the healthcare system. The primary required action by Siemens Medical Diagnostics was the systematic withdrawal of affected product models, specifications, and batches from the market. For comprehensive details concerning the specific products impacted and the full scope of the recall, stakeholders were advised to consult the accompanying "Medical Device Recall Event Report" attachment. This voluntary recall underscores the company's adherence to regulatory standards and its commitment to maintaining product quality and patient safety.